Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC47763 | Vevorisertib trihydrochloride Featured |
Vevorisertib (ARQ 751) (trihydrochloride) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM). Vevorisertib (trihydrochloride), as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations.
More description
|
![]() |
DC8458 | Akt Inhibitor VIII Featured |
Akt Inhibitor VIII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity (IC50 = 58 nM, 210 nM, and 2.12 μM; respectively).
More description
|
![]() |
DC74250 | TCMDC-136364 |
TCMDC-136364 (AKT Kinase Inhibitor) is an Akt kinase inhibitor, selectively inhibits Akt in proliferating cells expressing Trop-2, also potently inhibits P. falciparum multidrug resistant strain Dd2.
More description
|
![]() |
DC74249 | TAS0612 |
TAS0612 (TAS-0612) is an orally bioavailable multikinase inhibitor of AKT, p70S6K, and p90RSK, inhibits Y-box-binding protein (YBX1) phosphorylation.
More description
|
![]() |
DC10055 | Akt-I-1,2 HCl Featured |
The compound (Akt-I-1,2) inhibited both Akt1 and Akt2 with IC50 values of 2.7 and 21 μM respectively.
More description
|
![]() |
DC8333 | SC-79 Featured |
SC-79 is an activator of Akt; binds to the pleckstrin homology domain of Akt.
More description
|
![]() |
DC9273 | SC-66 Featured |
SC-66 is an allosteric inhibitor of Akt; interferes with pleckstrin homology domain binding to PIP3 and facilitates Akt ubiquitination.
More description
|
![]() |
DC7481 | PHT427 Featured |
PHT-427 is a dual Akt and PDPK1 inhibitor (high affinity binding for the PH domains of Akt and PDPK1) with Ki of 2.7 μM and 5.2 μM, respectively.
More description
|
![]() |
DC2021 | Perifosine (KRX-0401) Featured |
Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM.
More description
|
![]() |
DC7465 | MK-2206 2HCl Featured |
MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
More description
|
![]() |
DC2070 | GSK690693 Featured |
GSK690693 is a pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 2 nM, 13 nM, and 9 nM, respectively.
More description
|
![]() |
DC9335 | AT7867 Featured |
AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.
More description
|
![]() |
DC9972 | ARQ-092(Miransertib) Featured |
ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).
More description
|
![]() |
DC7994 | Afuresertib HCl Featured |
Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM).
More description
|
![]() |
DC5163 | A-674563 Featured |
A-674563 is a potent, orally available Akt1 inhibitor with an IC50 value of 11nM. Also displays activity against PKA and CDK2 with IC50 values of 16nM and 46nM respectively.
More description
|
![]() |
DC72234 | ALM301 |
ALM301 is an orally active highly specific AKT inhibitor with IC50 values of 0.13 µM, 0.09 µM and 2.75 µM for AKT1, AKT2 and AKT3, respectively. ALM301 inhibits AKT phosphorylation and modulates downstream signalling in vitro. ALM301 can inhibit cancer cell proliferation and tumor growth.
More description
|
![]() |
DC71182 | MS143 |
MS143 is a potent AKT degrader (DC50=46 nM and GI50=0.8 µM in PC3 cells). MS143 induces rapid and robust AKT degradation in a concentration- and time-dependent manner via hijacking the ubiquitin-proteasome system. MS143 can suppress cancer cell growth.
More description
|
![]() |
DC70160 | A-674563 hydrochloride |
A-674563 is a potent, selective and orally available AKT inhibitor with Ki of 11 nM (Akt1); increases the efficacy of paclitaxel in a PC-3 xenograft model; enhances the transcription of several chondrocyte marker genes, including Col2a1, Acan and Col11a2, in mouse primary chondrocytes by inhibiting Sox9 degradation through the ubiquitin-proteasome pathway; also suppresses FLT3-ITD positive AML both in vitro and in vivo.
More description
|
![]() |
DC50047 | AKT-IN-10 |
AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4).
More description
|
![]() |
DC50046 | AKT-IN-9 |
AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1).
More description
|
![]() |
DC49024 | AKT-IN-11 |
AKT-IN-11 is one of the most effective antibacterial agents against human hepatoma BEL-7402 cell line with an IC50 value of 1.15μM.
More description
|
![]() |
DC48722 | APN/AKT-IN-1 |
APN/AKT-IN-1 is a potent and dual inhibitor of APN and AKT with IC50s of 0.21 and 0.27 μM, respectively. APN/AKT-IN-1 can effectively inhibit the phosphorylation of GSK3β, the intracellular substrate of AKT.
More description
|
![]() |
DC8411 | Afuresertib Featured |
Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
More description
|
![]() |
DC10408 | BAY1125976 Featured |
BAY1125976 is a selective allosteric Akt1/2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.
More description
|
|
DC48030 | CCT128930 hydrochloride |
CCT128930 hydrochloride is a potent and selective inhibitor of AKT (IC50=6 nM). CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. Antitumor activity.
More description
|
![]() |
DC46919 | AKT-IN-6 |
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1).
More description
|
![]() |
DC46918 | Vevorisertib |
Vevorisertib (ARQ 751) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM). Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations.
More description
|
![]() |
DC46469 | Hu7691 |
Hu7691 is an orally active, selective Akt inhibitor with IC50s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice.
More description
|
![]() |
DC46468 | Hu7691 free base |
Hu7691 free base is an orally active, selective Akt inhibitor with IC50s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 free base inhibits tumor growth and enables decrease of cutaneous toxicity in mice.
More description
|
![]() |
DC45857 | PP2A Cancerous-IN-1 |
PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities.
More description
|
![]() |